Genomes and Genes
Summary: A serotonin uptake inhibitor that is effective in the treatment of depression.
Publications242 found, 100 shown here
- Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetineToru Kobayashi
Department of Molecular Neuropathology, Brain Research Institute, Niigata University, Niigata, Japan
J Pharmacol Sci 102:278-87. 2006b>Paroxetine is commonly used as a selective serotonin reuptake inhibitor for the treatment of depression and other psychiatric disorders. However, the molecular mechanisms of the paroxetine effects have not yet been sufficiently clarified...
- A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)Susan L McElroy
Lindner Center of HOPE Research Institute, Mason, OH 45040, USA
J Clin Psychiatry 71:163-74. 2010The aim of this study was to evaluate the efficacy and tolerability of quetiapine and paroxetine monotherapy for major depression in bipolar disorder.
- A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gamblingSuck Won Kim
Department of Psychiatry, University of Minnesota, Minneapolis, USA
J Clin Psychiatry 63:501-7. 2002This randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of paroxetine in the treatment of pathological gambling.
- Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findingsA L Brody
Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, CA, USA
Arch Gen Psychiatry 58:631-40. 2001..We also performed a preliminary comparison of regional changes with 2 distinct forms of treatment (paroxetine and interpersonal psychotherapy).
- Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trialJon E Grant
Department of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota 55454 1495, USA
Int Clin Psychopharmacol 18:243-9. 2003..The aim of the present study was to determine whether treatment with paroxetine in a large sample of subjects with pathological gambling would effectively diminish the severity of gambling ..
- A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depressionAdam B Burrows
Geriatrics Section, Boston University School of Medicine, 74 Fenwood Road, Boston, MA 02115, USA
Depress Anxiety 15:102-10. 2002..We conducted a randomized double-blind placebo-controlled 8-week trial comparing paroxetine and placebo in very old nursing home residents with non-major depression...
- A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorderDamiaan Denys
Department of Psychiatry, University Medical Center B 01 206, PO Box 85500, 3508 GA Utrecht, The Netherlands
J Clin Psychopharmacol 23:568-75. 2003..The current study compares the efficacy and tolerability of venlafaxine with paroxetine. One hundred and fifty patients with primary OCD according to DSM-IV criteria were randomly assigned in a 12-..
- Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis CC L Raison
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
Aliment Pharmacol Ther 25:1163-74. 2007..Whether antidepressants prevent depression during interferon-alpha/ribavirin treatment for hepatitis C virus infection has yet to be established...
- Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)Craig H Mallinckrodt
Lilly Research Laboratories, Indianapolis, Ind 46285, USA
Neuropsychobiology 56:73-85. 2007....
- Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruptionManfred Uhr
Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D 80804 Munich, Germany
Biol Psychiatry 54:840-6. 2003..used to examine the effect of the absence of the drug-transporting P-glycoprotein (P-gp) at the blood-brain barrier on the uptake of the antidepressants venlafaxine, paroxetine, mirtazapine, and doxepin and its metabolites into the brain.
- The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging studyJ H Meyer
Clarke Division, Centre for Addictions and Mental Health, Department ofPsychiatry, University of Toronto, Ontario, Canada
Am J Psychiatry 158:78-85. 2001..The objective of this study was to evaluate the effect of 6 weeks of paroxetine treatment on 5-HT(2A) receptors in depressed patients.
- The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tabletsJ Berwaerts
Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
Pharmacopsychiatry 42:158-63. 2009..As such, selecting antipsychotic medications with a low potential for drug-drug interactions (DDIs) is crucial, as many are extensively metabolized by hepatic cytochrome P450 (CYP) isozymes...
- Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled studyR D Marshall
Anxiety Disorders Clinic, Unit 69, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Am J Psychiatry 158:1982-8. 2001This study evaluated the efficacy and safety of paroxetine for the treatment of patients with chronic posttraumatic stress disorder (PTSD).
- A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis CBenjamin J Morasco
Behavioral Health and Clinical Neurosciences Division, Portland VA Medical Center, Oregon, United States
J Affect Disord 103:83-90. 2007..This study examined the efficacy of paroxetine in preventing the development of depression during antiviral therapy.
- Clinical and neurobiological effects of tianeptine and paroxetine in major depressionThomas Nickel
Max Planck Institute of Psychiatry, Munich, Germany
J Clin Psychopharmacol 23:155-68. 2003..between these two opposite pharmacological modes of action, we compared the changes induced by tianeptine and paroxetine on psychopathology, the hypothalamic-pituitary-adrenocortical (HPA) system, and cognitive functions in a double-..
- Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetineEric Hollander
Department of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029 6574, USA
J Clin Psychiatry 64:1113-21. 2003..This study evaluated the acute safety and efficacy and long-term efficacy, safety, and impact on relapse prevention of paroxetine in obsessive-compulsive disorder.
- State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetineH Murck
Max Planck Institute of Psychiatry, Munich, Germany
Neuropsychopharmacology 28:348-58. 2003Tianeptine enhances while paroxetine inhibits serotonin reuptake into neurons; however, both show an antidepressive action...
- Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's diseaseYoung C Chung
Neuroscience Graduate Program, School of Medicine, Ajou University, Suwon, South Korea
J Immunol 185:1230-7. 2010The present study examined whether the antidepressant paroxetine promotes the survival of nigrostriatal dopaminergic (DA) neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease...
- Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?Daniel A Geller
Obsessive Compulsive Disorder Program, Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
J Child Adolesc Psychopharmacol 13:S19-29. 2003To examine the influence of psychiatric comorbidity on response and relapse rates in children and adolescents treated with paroxetine for obsessive-compulsive disorder (OCD).
- Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndromeYusuke Murata
Department of Psychosomatic Medicine, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
J Clin Psychopharmacol 30:11-7. 2010b>Paroxetine discontinuation symptoms can at times be severe enough to reduce the quality of life...
- Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumpsPeng Wei
Division of Medicinal and Natural Products Chemistry, The University of Iowa, Iowa City, IA 52242, USA
Bioorg Med Chem Lett 14:3093-7. 2004In this study the chemical modification of paroxetine was employed to determine which structural differences between the paroxetine-like and femoxetine-like selective serotonin reuptake inhibitors is responsible for the differential ..
- Effect of paroxetine on enhanced contextual fear induced by single prolonged stress in ratsTerumichi Takahashi
Department of Psychiatry and Neurosciences, Division of Frontier Medical Science, Hiroshima University, Minami-ku, Hiroshima, 734-8551, Japan
Psychopharmacology (Berl) 189:165-73. 2006..can produce an enhanced psychophysiological reactivity to laboratory stressors unrelated to trauma and whether paroxetine (PRX) can alleviate the enhanced anxiety and fear response in rats subjected to SPS...
- A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorderG J Hendriks
Forum GGz Nijmegen, Department for Anxiety Disorders Overwaal, Nijmegen, The Netherlands
Acta Psychiatr Scand 122:11-9. 2010To examine the effectiveness of paroxetine and cognitive-behavioural therapy (CBT) in elderly patients suffering from panic disorder with or without agoraphobia (PD(A)).
- The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depressionAndre Tadic
Department of Psychiatry, University of Mainz, Mainz, Germany
Am J Med Genet B Neuropsychiatr Genet 144:325-31. 2007..association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled ..
- Brain creatine kinase activity is increased by chronic administration of paroxetinePatricia M Santos
Laboratório de Fisiopatologia Experimental, Programa de Pos Graduacao em Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, SC, Brazil
Brain Res Bull 80:327-30. 2009..modulate energy metabolism, we decided to investigate CK activity from rat brain after chronic administration of paroxetine (selective serotonin reuptake inhibitor), nortriptiline (tricyclic antidepressant) and venlafaxine (selective ..
- Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patientsReiji Yoshimura
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan
Hum Psychopharmacol 24:489-94. 2009..the relationship between the serotonin transporter gene linked polymorphic regions (5-HTTLPR) or plasma paroxetine levels and clinical response to paroxetine in depressed patients...
- Tryptophan hydroxylase gene associated with paroxetine antidepressant activityA Serretti
Department of Psychiatry, Vita Salute University, San Raffaele Institute, Via Stamira D Ancona 20 20127 Milan, Italy
Eur Neuropsychopharmacol 11:375-80. 2001..possible association of the A218C tryptophan hydroxylase (TPH) gene variant with the antidepressant activity of paroxetine was investigated in a sample of 121 inpatients affected by a major depressive episode and treated with ..
- Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopramS J Wilson
Psychopharmacology Unit, University of Bristol, University Walk, Bristol BS8 1TD, UK
Eur Neuropsychopharmacol 14:367-72. 2004..Although in the UK, paroxetine (PAR) and citalopram (CIT) have recommended doses of 20 mg/day for the treatment of depression, the recommended ..
- An open trial of paroxetine for the "offensive subtype" of taijin kyofusho and social anxiety disorderToshihiko Nagata
Department of Neuropsychiatry, Osaka City University Medical School, Osaka, Japan
Depress Anxiety 23:168-74. 2006..This study investigated the efficacy of the SSRI paroxetine in patients with the TKS offensive subtype, both on anxiety and fears, as well as insight...
- Effect of corticosterone and paroxetine on masculine mating behavior: possible involvement of neurogenesisBenson Wui Man Lau
Department of Anatomy, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
J Sex Med 8:1390-403. 2011..Together with the neurogenesis-inhibiting effect of corticosterone, we hypothesize that cell proliferation in the olfactory system is essential for male rodent sexual functioning...
- Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetineMikael Landen
Section of Psychiatry St Göran, Department of Clinical Neuroscience, Karolinska Institutet, SE 112 81, Stockholm, Sweden
J Clin Psychiatry 66:100-6. 2005....
- Venlafaxine extended release vs placebo and paroxetine in social anxiety disorderMichael R Liebowitz
New York State Psychiatric Institute, New York 10032, USA
Arch Gen Psychiatry 62:190-8. 2005..Evidence indicates that venlafaxine hydrochloride extended release (ER) effectively ameliorates anxiety symptoms...
- Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphismMasaki Kato
Department of Neuropsychiatry, Kansai Medical University, Moriguchi, Osaka, Japan
Int Clin Psychopharmacol 20:151-6. 2005..Clinical responses to paroxetine and fluvoxamine were evaluated by total and cluster depressive symptoms for 81 Japanese patients who were ..
- Recurrent paroxetine-induced hyponatremiaAsif R Malik
Can J Psychiatry 49:785. 2004
- Perinatal outcome following third trimester exposure to paroxetineAdriana Moldovan Costei
The Motherisk Program, Division of Clinical Pharmacology/Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada
Arch Pediatr Adolesc Med 156:1129-32. 2002BACKGROUND: Paroxetine hydrochloride is commonly used for maternal depression, panic disorder, and obsessive-compulsive disorder. The drug readily crosses the human placenta...
- Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensionsDan J Stein
University of Cape Town, South Africa and University of Florida, Gainesville, USA
Eur Neuropsychopharmacol 16:33-8. 2006..This paper examines data from a fixed-dose trial of escitalopram versus paroxetine, in order to determine the differential effects of these agents on symptom dimensions in social anxiety disorder ..
- Paroxetine-induced somnambulismToshiro Kawashima
J Clin Psychiatry 64:483. 2003
- Serotonergic activity measured by platelet [3H]paroxetine binding in patients with eating disordersCarla E Ramacciotti
Department of Psychiatry, Pharmacology, Neurobiology and Biotechnologies, Section of Psychiatry, University of Pisa, Italy
Psychiatry Res 118:33-8. 2003..aim of the present study was to verify whether differences in serotonergic activity, measured by platelet [3H]paroxetine binding, would validate current ED classification...
- Triiodothyronine addition to paroxetine in the treatment of major depressive disorderBente C Appelhof
Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, The Netherlands
J Clin Endocrinol Metab 89:6271-6. 2004..This is the first study to investigate the efficacy of T3 addition to paroxetine in major depression...
- Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind studyA Bertani
Anxiety Disorder Clinical and Research Unit, Department of Neuropsychiatric Sciences, Vita Salute University, Istituto Scientifico Ospedale San Raffaele, Milan, Italy
Pharmacopsychiatry 37:206-10. 2004..However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD.
- Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetineP C McHugh
Department of Pathology, University of Otago, Christchurch, New Zealand
J Psychopharmacol 24:1243-51. 2010..Rats were administered either 5 mg/kg daily of the antidepressant paroxetine or vehicle for 12 days, then hippocampal protein was recovered and resolved by 2-D gel electrophoresis...
- MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depressionAlma Mihaljevic Peles
Department of Psychiatry, Zagreb University Hospital and University School of Medicine, Kispaticeva 12, 10 000 Zagreb, Croatia
Prog Neuropsychopharmacol Biol Psychiatry 32:1439-44. 2008..the potential influence of MDR1 polymorphisms, exon 26 C3435T and exon 21 G2677T/A, on treatment response to paroxetine (20 mg/day) in patients with major depression...
- Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled studyE Di Girolamo
Cardiovascular Clinic Institute G D Annunzio University, Chieti, Italy
J Am Coll Cardiol 33:1227-30. 1999The purpose of the study was to determine whether the well tolerated serotonin reuptake inhibitor paroxetine hydrochloride could prevent vasovagal syncope in patients resistant to or intolerant of previous traditional therapies.
- The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back painC Dickens
Department of Psychiatry, Manchester University, UK
Psychosomatics 41:490-9. 2000..Using a placebo-controlled trial, the authors examined the analgesic and antidepressant efficacy of paroxetine (20 mg) in chronic low back pain sufferers...
- Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancyAdrienne Einarson
Motherisk Program, Hospital for Sick Children, Division of Clinical Pharmacology, University of Toronto, 555 University Ave, Toronto, Ontario M5G 1X8, Canada
Am J Psychiatry 165:749-52. 2008..several studies noted an increased risk of cardiovascular birth defects associated with maternal use of paroxetine compared with other antidepressants in the same class...
- Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetinePatrick C McHugh
Department of Pathology, University of Otago, Christchurch, New Zealand
J Neurosci Res 86:306-16. 2008..and glial cells by controlled differentiation of mouse embryonic stem cells, followed by exposure to 1 microM paroxetine for 14 days...
- Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivityU W Preuss
Department of Psychiatry, Ludwig Maximilians Universitat Munchen, Nussbaumstr 7, 80336, Munchen, Germany
Psychiatry Res 96:51-61. 2000The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (5-HTT) polymorphism (5-HTTLPR)...
- Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS studyM E Henry
McLean Hospital, Belmont, MA 02478, USA
Am J Psychiatry 157:1506-8. 2000..This study tested whether a relationship exists between concentration and response following discontinuation of selective serotonin reuptake inhibitors...
- Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokineticsMagi Farre
Pharmacology Research Unit, Institut Municipal d Investigació Mèdica Hospital del Mar, Doctor Aiguader 88, E 08003 Barcelona, Spain
J Pharmacol Exp Ther 323:954-62. 2007..A clinical trial was designed where subjects pretreated with paroxetine, one of the most potent inhibitors of both 5-hydroxytryptamine reuptake and CYP2D6 activity, were challenged ..
- Decreased platelet 3H-paroxetine binding in untreated panic disorder patientsD Marazziti
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, Italy
Life Sci 65:2735-41. 1999..We therefore evaluated the binding of 3H-paroxetine, a selective 5-HT reuptake inhibitor which is considered the ligand of choice for labelling the 5-HT transporter,..
- ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorderMasaki Kato
Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
Prog Neuropsychopharmacol Biol Psychiatry 32:398-404. 2008..3 functional ABCB1 polymorphisms (C3435T: rs1045642, G2677T/A: rs2032582 and C1236T: rs1128503) with response to paroxetine in a Japanese major depression sample followed for 6 weeks...
- A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizersEduard Vieta
Bipolar Disorders Program, Barcelona Stanley Foundation Research Center, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
J Clin Psychiatry 63:508-12. 2002..This study was aimed to assess and compare the efficacy and safety of 2 different antidepressant drugs, paroxetine and venlafaxine, in this indication.
- ParoxetineSiu Wa Tang
University of California, Psychiatry North Campus Zot 1681, Irvine, California 92697 1681, USA
Expert Opin Pharmacother 9:787-94. 2008b>Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients.
- Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nauseaMisuzu Tanaka
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
Int J Neuropsychopharmacol 11:261-7. 2008..type 2A, 3A, and 3B (5-HT3B) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea...
- Toxic hepatitis associated with paroxetineO Colakoglu
Gastroenterology Clinics, Ataturk Training and Research Hospital, Izmir, Turkey
Int J Clin Pract 59:861-2. 2005Hepatotoxicity is a rare complication of paroxetine, a selective serotonin reuptake inhibitor...
- Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan studyR Zanardi
Istituto Scientifico Ospedale San Raffaele, Department of Neuropsychiatric Sciences, School of Medicine, University of Milan, Italy
J Clin Psychopharmacol 21:53-8. 2001..binding of [18F]fluoro-ethyl-spiperone after a 4-week treatment with the selective serotonin reuptake inhibitor paroxetine. [18F]fluoro-ethyl-spiperone labels 5-HT2A receptors in the cortex and dopamine D2 receptors in the basal ..
- Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trialM H Pollack
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
J Clin Psychiatry 62:350-7. 2001The objective of this randomized, double-blind, placebo-controlled study was to investigate the efficacy and safety of paroxetine in outpatients with generalized anxiety disorder (GAD).
- Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levelsN P Tatonetti
Biomedical Informatics Training Program, Stanford University, Stanford, California, USA
Clin Pharmacol Ther 90:133-42. 2011The lipid-lowering agent pravastatin and the antidepressant paroxetine are among the most widely prescribed drugs in the world. Unexpected interactions between them could have important public health implications...
- Effect of aging and sex on the [3H]-paroxetine binding to human plateletsD Marazziti
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotechnologie, University of Pisa, Italy
J Affect Disord 50:11-5. 1998..5-HT) transporter, we reinvestigated this matter by comparing the binding of the more selective ligand [3H]-paroxetine in 20 aged and 23 young subjects...
- Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology ProgramGary R Morrow
James P Wilmot Cancer Center and Department of Biostatistics, University of Rochester Medical Center, NY 14642, USA
J Clin Oncol 21:4635-41. 2003..This randomized clinical trial tested whether paroxetine, a selective serotonin reuptake inhibitor antidepressant known to modulate brain serotonin, would reduce fatigue ..
- Prenatal maternal paroxetine treatment and neonatal mortality in the rat: a preliminary studyDaniel L A van den Hove
Department of Psychiatry and Neuropsychology, Research Institute Brain and Behavior, European Graduate School of Neuroscience, Maastricht University, Maastricht, The Netherlands
Neonatology 93:52-5. 2008..Our aim was to examine the efficacy of using the selective serotonin reuptake inhibitor, paroxetine, to alleviate the symptoms of prenatal maternal stress in Fisher 344 rats...
- Neonatal paroxetine withdrawal syndromeJ A Stiskal
Division of Neonatology, Morristown Memorial Hospital, Morristown, New Jersey, USA
Arch Dis Child Fetal Neonatal Ed 84:F134-5. 2001Four term neonates presented with symptoms such as jitteriness and necrotising enterocolitis after paroxetine exposure in utero.
- Antidepressant medications in childrenBenedetto Vitiello
National Institute of Mental Health, Bethesda, MD, USA
N Engl J Med 350:1489-91. 2004
- Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography studyJeffrey H Meyer
Clarke Site, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, 250 College St, Toronto, Ont M5T 1R8, Canada
Am J Psychiatry 161:826-35. 2004Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT)...
- Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitorsJohn F Cryan
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
Proc Natl Acad Sci U S A 101:8186-91. 2004..Surprisingly, the effects of the selective serotonin reuptake inhibitors (SSRIs) fluoxetine, sertraline, and paroxetine were also absent or severely attenuated in the Dbh(-/-) mice...
- Impact of pain on depression treatment response in primary careMatthew J Bair
Regenstrief Institute and the Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
Psychosom Med 66:17-22. 2004..Pain commonly coexists with depression, but its impact on treatment outcomes has not been well studied. Therefore, we prospectively evaluated the impact of comorbid pain on depression treatment response and health-related quality of life...
- Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trialEdward B Perry
Department of Psychiatry, VA Connecticut Healthcare System, Psychiatry Service 116A, 950 Campbell Avenue, West Haven, CT 06516, USA
J Clin Psychiatry 65:238-43. 2004..Here, we report on a double-blind, randomized, controlled 6-week study of pindolol augmentation of selective serotonin reuptake inhibitors (SSRIs) in depressed outpatients resistant to SSRI monotherapy...
- [Pharmacotherapy of generalized anxiety disorder: state of the art]D F Zullino
Departement universitaire de psychiatrie adulte, Prilly Lausanne
Praxis (Bern 1994) 92:1775-9. 2003..Newer antidepressants are recommended as basic treatment, especially venlafaxine and paroxetine, which are licensed for that indication.
- Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetineMelissa J Joliat
J Clin Psychopharmacol 24:464-7. 2004
- Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorderMadhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
J Clin Psychopharmacol 24:497-506. 2004..The purpose of this retrospective analysis was to estimate the cost and effectiveness of venlafaxine extended-release (VXR) compared with selective serotonin reuptake inhibitors in the outpatient treatment of major depressive disorder...
- [Selective serotonin reuptake inhibitors--current knowledge]Dominika Dudek
Psychiatr Pol 38:507-24. 2004..The paper contains data about the most common and typical side effects and possible drug interactions. The reports and information about new therapeutic proposals concerning SSRI's are also discussed...
- Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?D N Bateman
Scottish Poisons Information Bureau NPIS Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, EH10 4SA Edinburgh, Scotland
Eur J Clin Pharmacol 60:221-4. 2004..To investigate likelihood of self-harm by overdose with antidepressant drugs of different types by examining hospital admission data and poisons inquiries and relating them to prescribing...
- Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitorsEllen M Whyte
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
J Clin Psychiatry 65:1634-41. 2004....
- Do venlafaxine XR and paroxetine equally influence negative and positive affect?Gabriel S Dichter
Department of Psychology, College of Arts and Sciences, Wilson Hall, Vanderbilt University, Nashville TN 37203, USA
J Affect Disord 85:333-9. 2005We assessed the therapeutic effects of venlafaxine XR and paroxetine on mood and anxiety symptoms derived from the tripartite model of mood...
- An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorderMatthew A Menza
J Clin Psychopharmacol 27:207-10. 2007
- Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patientsReiji Yoshimura
Department of Psychiatry, University of Occupational and Environmental Health, 1 1 Iseigaoka, Yahatanishi ku, Kitakyushu, Fukuoka, Japan
Prog Neuropsychopharmacol Biol Psychiatry 31:1034-7. 2007..In the present study, we investigated the effects of paroxetine, an SSRI, and milnacipran, an SNRI, on serum BDNF levels in depressed patients...
- Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005)Anita C Volkers
NIVEL, Utrecht, The Netherlands
Pharmacoepidemiol Drug Saf 16:1054-62. 2007..To study the use of antidepressants in children and adolescents in Dutch general practice in 2001 and 2005 and to determine off-label prescribing...
- A monoamine oxidase B gene variant and short-term antidepressant treatment responseAndre Tadic
Department of Psychiatry, University of Mainz, Untere Zahlbacher Str 8, 55131 Mainz, Germany
Prog Neuropsychopharmacol Biol Psychiatry 31:1370-7. 2007..controlled clinical trial, conducted at 50 centers in Germany, comparing the efficacy of mirtazapine and paroxetine during 6 weeks of treatment...
- Benefits and harms of pediatric antidepressant medicationsJonathan L Edwards
JAMA 298:626-7; author reply 627. 2007
- Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST)Gian Marco Leggio
Department of Experimental and Clinical Pharmacology, University of Catania Medical School, 95125 Catania, Italy
Eur Neuropsychopharmacol 18:271-7. 2008..compound, clomipramine (1, 5 and 10 mg/kg) or of one the selective serotonin reuptake inhibitors (SSRIs), paroxetine, sertraline or citalopram (1, 4 and 16 mg/kg), 30 min prior the behavioral test...
- Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIsCharles B Nemeroff
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Biol Psychiatry 63:424-34. 2008To compare venlafaxine and selective serotonin reuptake inhibitors (SSRIs; fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram) in the treatment of depression.
- Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic studyAntonio Tundo
Institute of Psychopathology, Rome, Italy
J Clin Psychiatry 68:1552-6. 2007..The purpose of the present study is to examine the effectiveness of CBT on a sample of nonselected, pharmacologically treatment-resistant OCD patients...
- Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transitionT Ushiroyama
Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka 569 8686, Japan
J Med 35:151-62. 2004To evaluate the efficacy of the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine in treating depression in the menopausal transition and to compare their efficacy, safety, side-effect profiles and drug compliance...
- Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trialDavid Brent
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
JAMA 299:901-13. 2008..There are no data to guide clinicians on subsequent treatment strategy...
- Successful treatment of refractory hypochondriasis with duloxetinePierluigi Politi
Prog Neuropsychopharmacol Biol Psychiatry 31:1145-6. 2007
- Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid programAnn M Hamer
Drug Use Research and Mangement Program, Oregon State University College of Pharmacy, Portland, OR 97201 4952, USA
J Manag Care Pharm 12:449-56. 2006..Dose form optimization can reduce the direct cost of therapy by up to 50% while continuing the same daily dose of the same drug molecule...
- Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treatJohn Cookson
Department of Psychiatry, The Royal London Hospital, London, UK
Int Clin Psychopharmacol 21:267-73. 2006..The NNTs for selective serotonin reuptake inhibitors (fluoxetine or paroxetine, 20 mg/day) were around 7 for response, 11 for remission, and 8 for CGI-defined improvement...
- Are SSRIs really more effective for anxious depression?Michael J Panzer
Fox Valley Psychiatric Associates, Appleton, WI 54915, USA
Ann Clin Psychiatry 17:23-9. 2005..Many psychiatrists assume that anxious depression is more responsive to SSRIs than to other antidepressants. The purpose of this literature review was to determine if SSRIs or any other antidepressants are superior...
- [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)]L Hjalmarsson
, Institut Mutualiste Montsouris, 42 Boulevard Jourdan, 75014 Paris
Encephale 31:309-16. 2005..8% more for paroxetine and between 16 to 24% more for fluoxetine...
- Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overviewJ L Carrasco
Servicio de Psiquiatria, , Madrid, Spain
Int J Clin Pract 59:1428-34. 2005..By understanding the properties of SSRIs and employing careful selection of agents for individual patients, physicians are more able to tailor antidepressant treatments to their patients' particular circumstances...
- Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European originBárbara Arias
Unitat d Antropologia, Departament de Biologia Animal, Facultat de Biologia, Universitat de Barcelona, Diagonal 645, 08028 Barcelona, Spain
J Affect Disord 90:251-6. 2006..The COMT gene might be a good candidate for explaining some aspects of the pharmacological response to SSRIs...
- Immediate switching of antidepressant therapy: results from a clinical trial of duloxetineMadelaine M Wohlreich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Ann Clin Psychiatry 17:259-68. 2005..We examined the efficacy and tolerability associated with a switch from a selective serotonin reuptake inhibitor (SSRI) or venlafaxine to duloxetine...
- Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studiesMostafa El Mansari
Laboratory of Neuropharmacology and Neurochemistry, Faculty of Pharmacy, University of Claude Bernard Lyon I, INSERM EA 512, Lyon, France, and Department of Biological Psychiatry, Aarhus Psychiatric University Hospital, Risskov, Denmark
Int J Neuropsychopharmacol 10:31-40. 2007..reuptake inhibitors (SSRIs) known to act on allosteric sites namely escitalopram, and to a lesser extent paroxetine, compared to fluoxetine, which has no affinity for these sites...
- Selective serotonine reuptake inhibitors prevents emotional lability in healthy subjectsM Scoppetta
Psychiatric Institute, Catholic University, Rome, Italy
Eur Rev Med Pharmacol Sci 9:343-8. 2005..EL can be present in healthy subjects as well, in whom it is considered as normal, although often embarrassing...
- A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorderDavid S Baldwin
Clinical Neuroscience Division, University of Southampton, Royal South Hants Hospital, Southampton, UK
Int Clin Psychopharmacol 21:159-69. 2006..study evaluated the short- and long-term antidepressant tolerability and efficacy of escitalopram and paroxetine. Tolerability was assessed by monitoring adverse events throughout the study, and discontinuation events during ..
- Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteersPierre Blier
Department of Psychiatry, McGill University, Montreal, QC, Canada
Int J Neuropsychopharmacol 10:41-50. 2007..Healthy male volunteers received, on a double-blind basis, paroxetine (20 mg/d), desipramine (100 mg/d), nefazodone (300 mg/d), or venlafaxine (150 or 300 mg/d) in the last 5 d of a ..
- [Effectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder]L Agüera-Ortiz
Servicio de Psiquiatria, Hospital Universitario Doce de Octubre, Madrid
Actas Esp Psiquiatr 34:153-61. 2006....
- [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents]Daniel Bailly
service hospitalo universitaire de psychiatrie, Hopital Sainte Marguerite, Marseille 13
Presse Med 35:1507-15. 2006..Their use should be reserved for severe disorders or when psychotherapy alone has been shown to be inadequate, and when they are used, efficacy and side effects must be monitored carefully and frequently...
- A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunctionCindy M Meston
Department of Psychology, University of Texas at Austin, Austin, Texas, USA
J Sex Marital Ther 30:57-68. 2004..Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (..
- Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depressionPaola Rocc
Psychiatric Section, Department of Neuroscience, University of Turin, Via Cherasco 11, 10126 Turin, Italy
Prog Neuropsychopharmacol Biol Psychiatry 26:1155-60. 2002..A tempting approach to examine alterations of dopaminergic system in major depression is to examine the expression of dopamine receptors in peripheral blood mononuclear cells (PBMC)...
- Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effectsSidney H Kennedy
Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario, Canada
J Clin Psychiatry 63:181-6. 2002..This study was designed to evaluate the effect of combining bupropion sustained release (SR) with venlafaxine, paroxetine, or fluoxetine in patients who reported unacceptable sexual dysfunction when treated with monotherapy with the ..
- 5-HT1A RECEPTOR/G PROTEIN COUPLING AND ADAPTATIONEmanuel Meller; Fiscal Year: 2003..in forebrain regions will be assessed to test the hypothesis that repeated treatment (21 days) with ipsapirone, paroxetine or clorgyline (but not imipramine) will desensitize somatodendritic 5-HT1A autoreceptors and reduce agonist-..
- R21 Project: St. John's Wort vs. Placebo in OCDKenneth Kobak; Fiscal Year: 2003..g., drop-out rates in the multi-center trials of fluoxetine, fluvoxamine, sertraline, and paroxetine were 23%, 24%, 27%, and 20% respectively. There has been considerable worldwide interest in St...
- GENETIC ANALYSIS OF NEMATODE EGG LAYINGHOWARD R HORVITZ; Fiscal Year: 2010....
- Paradoxical Antidepressant Action in Locus Coeruleus during DevelopmentJAY WEISS; Fiscal Year: 2009..to juveniles (children and adolescents), (2) use of selective serotonin reuptake inhibitors (SSRIs), especially paroxetine, and (3) effects during the early course of AD treatment...
- Paradoxical Antidepressant Action in Locus Coeruleus during DevelopmentJAY WEISS; Fiscal Year: 2007..to juveniles (children and adolescents), (2) use of selective serotonin reuptake inhibitors (SSRIs), especially paroxetine, and (3) effects during the early course of AD treatment...
- Ginkgo Biloba: Antidepressant-Induced Sexual DysfunctionCindy Meston; Fiscal Year: 2003..female sexual arousal disorder, and/or inhibited female orgasm secondary to either to fluoxetine, sertraline, or paroxetine use...
- Maintenance Therapies in Late-Life Depression-IIIBruce Pollock; Fiscal Year: 2007..of memory and of executive functions despite continued recovery from depression on SSRI pharmacotherapy with paroxetine. Therefore, in MTLD-III, we will test a pharmacologic strategy involving the cholinesterase inhibitor (ChEI) ..
- Maintenance Therapies in Late-Life Depression-IIICharles Reynolds; Fiscal Year: 2004..of memory and of executive functions despite continued recovery from depression on SSRI pharmacotherapy with paroxetine. Therefore, in MTLD-III, we will test a pharmacologic strategy involving the cholinesterase inhibitor (ChEI) ..
- GERIATRIC DEPRESSION--NEUROBIOLOGY OF TREATMENTCharles Reynolds; Fiscal Year: 2003..We hypothesize that therapeutic sleep deprivation (TSD) will accelerate response to paroxetine (PX), as compared with TSD (+ placebo) or with PX alone...
- RATIONAL PHARMACOTHERAPY OF PRIMARY INSOMNIADaniel Buysse; Fiscal Year: 2004..activities will focus on design and implementation of a treatment trial comparing a Bz (zolpidem) and an AD (paroxetine) versus placebo for the acute and maintenance treatment of PI...
- TREATMENT OF PANIC DISORDER LONG TERM STRATEGIESM Shear; Fiscal Year: 2003..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
- TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIESDavid Barlow; Fiscal Year: 2003..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
- SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGINGHANK KUNG; Fiscal Year: 2004..prescribed antidepressants, selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline and paroxetine, modulate 5-HT neurotransmission by blocking the serotonin transporters (SERT)...
- PSYCHOSTIMULANT RECOGNITION BY SEROTONIN TRANSPORTERSERIC BARKER; Fiscal Year: 2007..Antidepressants such as paroxetine, fluoxetine, and imipramine bind to the transporter and inhibit serotonin uptake, thereby prolonging the ..
- St. John's Wort vs Placebo in Social PhobiaKenneth Kobak; Fiscal Year: 2002..However, side effects with these compounds suggests the need for better tolerated compounds, e.g., in the paroxetine multi-center trial (the only drug with an FDA approved indication), 27 percent reported somnolence, 26 percent ..
- MLSN Screen of the PD Alpha Synuclein 5'UTRJack Rogers; Fiscal Year: 2007..the 5'UTRs of neurodegenerative disease transcripts, our APP 5'UTR screens generated drug selectivity since paroxetine was an APP 5'UTR directed FDA inhibitor that did not change APLP-1 and APLP-2 expression in SH-SY5Y cells (..
- Prazosin for Noncombat Trauma PTSDMurray Raskind; Fiscal Year: 2007..and sleep disturbance that persist despite a trial of the selective serotonin reuptake inhibitor (SSRI) paroxetine. Although several SSRIs are FDA-approved for PTSD, SSRIs (and other drugs) often are not helpful for these very ..
- AFFECT, DEPRESSION AND BRAIN ASYMMETRYRichard Davidson; Fiscal Year: 2001..First during an acute episode when all patients are off medication. Second, patients will then be treated with paroxetine and will be retested after meeting criteria for recovery...